Vermont Immunobiology / Infectious Diseases Center

佛蒙特州免疫生物学/传染病中心

• 批准号: 10006835
• 负责人: Ralph C Budd
• 金额: $ 116.48万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-05 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10006835
• 关键词: Area; Atmosphere; Avian Influenza; Award; Bacterial Infections; Bangladesh; Basic Science; Bioinformatics; Categories; Centers of Research Excellence; Child; Clinical; Clinical Trials; Commercial Sectors; Communicable Diseases; Core Facility; Dengue; Dengue Vaccine; Development; Diagnostic; Disease Outbreaks; Ebola; Educational workshop; Emerging Communicable Diseases; Environment; Faculty; Fostering; Foundations; Funding; Genome; Grant; Health; Home environment; Human poliovirus; Immune response; Immunobiology; Immunology; Infection; Infrastructure; Investigation; Joints; Laboratories; Legal patent; Mass Spectrum Analysis; Massive Parallel Sequencing; Measles virus; Mentors; Methodology; Microbiology; Middle East Respiratory Syndrome; National Institute of Allergy and Infectious Disease; Paper; Parasitic infection; Pathogenesis; Phase; Pilot Projects; Poliomyelitis; Post-Translational Protein Processing; Program Research Project Grants; Proteomics; Public Health; Publications; Publishing; Research; Research Personnel; Research Project Grants; Scientific Advances and Accomplishments; Scientist; Series; Structure; Talents; Technology; Therapeutic; Time; Training; United States National Institutes of Health; Universities; Vermont; Virulent; Virus Diseases; Wing; Writing; base; biosafety level 3 facility; college; experience; innovation; instrumentation; interest; mass spectrometer; metabolomics; microbial; mid-career faculty; multidisciplinary; next generation sequencing; novel vaccines; pathogen; programs; public health relevance; response; senior faculty; skills; sound; tenure track; vaccine evaluation; working group

The Vermont Center for Immunology and Infectious Diseases (VCIID) COBRE is about to enter its 10th year. During this period, VCIID has grown from 9 founding faculty to 25 and produced 416 publications and $92 million in grant support and 14 patents. Twelve junior faculty were supported with COBRE funding during Phases I and II (10 tenure track and 5 have already achieved tenure) and they published 118 papers and garnered $13.2 million in funding (including 4 new R01 grants) while still junior faculty. Junior faculty also received several awards, including a Pew Scholars Award. Institutional support from the University of Vermont (UVM) during this period was also a robust $2.9 million. The VCIID has demonstrated its development into a mature collaborative center by a variety of metrics. Its faculty has received a P01 Program Project Grant and a T32 Training Grant, both of which were renewed. One of the former junior faculties has established the Vaccine Testing Center (VTC) as a clinical trials wing of the VCIID. It is currently conducting trials for a new dengue virus vaccine with NIAID funding, and examining why undernourished children in Bangladesh do not respond to polio virus with funding from the Bill & Melinda Gates Foundation. To date VTC has received $18.5 million in funding. To fulfill a growing need for a BSL3 facility for VCIID faculty, we were economically innovative by leveraging a COBRE ARRA supplement to support a collaborative venture with the Vermont Department of Health in which UVM donated land on the UVM campus to build a new Department of Health laboratory containing a large joint BSL3/ABSL3 facility paid and maintained by the Department of Health. This will also foster interactions between VCIID investigators and Department of Health staff, and hence move us into the realm of public health. As we approach Phase III we will motivate VCIID faculty through a Pilot project Program to collaborate on common research themes to prepare for new collaborative R01, P01 and U-19 applications, as well as to move their research in a translational and entrepreneurial direction with our new SPARK-VT Program. Our cores in Genome Technologies/Bioinformatics and Mass Spectrometry/Proteomics have both upgraded instrumentation during Phase II and diversified their user base. Combined with institutional commitments for five years beyond the end of Phase III, we feel we have achieved the metrics to begin a successful Phase III COBRE period.

佛蒙特州免疫学和传染病中心（VCIID） COBRE即将进入其第10个年头。在此期间，VCIID从9名创始教师发展到25名，发表了416篇论文，获得了9200万美元的资助和14项专利。12名初级教师在第一和第二阶段获得了COBRE资助（10名终身教职人员和5名已经获得终身教职人员），他们发表了118篇论文，获得了1320万美元的资助（包括4名新的R01补助金）。青年教师还获得了包括皮尤学者奖在内的多个奖项。在此期间，佛蒙特大学（UVM）的机构支持也达到了290万美元。VCIID已经通过各种指标证明了它已经发展成为一个成熟的协作中心。其教师已获得P01计划项目资助和T32培训资助，这两项资助均已续期。前初级学院之一成立了疫苗试验中心（VTC），作为VCIID的临床试验部门。它目前正在NIAID的资助下进行一种新的登革热病毒疫苗的试验，并在比尔和梅林达·盖茨基金会的资助下研究孟加拉国营养不良儿童对脊髓灰质炎病毒没有反应的原因。职训局至今已获资助1,850万元。为了满足VCIID教师对BSL3设施日益增长的需求，